AR085490A1 - Una formulacion de vacuna liposomal - Google Patents
Una formulacion de vacuna liposomalInfo
- Publication number
- AR085490A1 AR085490A1 ARP120100627A AR085490A1 AR 085490 A1 AR085490 A1 AR 085490A1 AR P120100627 A ARP120100627 A AR P120100627A AR 085490 A1 AR085490 A1 AR 085490A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- independently
- formula
- vaccine formulation
- adjuvant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 11
- 238000009472 formulation Methods 0.000 title abstract 10
- 229960005486 vaccine Drugs 0.000 title abstract 9
- 150000002632 lipids Chemical class 0.000 abstract 7
- 239000002671 adjuvant Substances 0.000 abstract 6
- 229910019142 PO4 Inorganic materials 0.000 abstract 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 5
- 239000010452 phosphate Substances 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000006850 spacer group Chemical group 0.000 abstract 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 abstract 2
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 abstract 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 abstract 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 abstract 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Formulaciones de vacunas liposomales con glucolipopéptidos, que comprenden un coadyuvante y un inmunógeno, que pueden usarse en la inmunoterapia y/o el tratamiento del cáncer.Reivindicación 1: Una formulación de vacuna liposomal, caracterizada porque comprende: (a) un péptido que comprende al menos dos copias de una repetición en tándem de núcleo: TSAPDTRPAPGSTAPPAHGV, (SEQ ID Nº 1) o una secuencia al menos 85% idéntica a SEQ ID Nº 1, o permutaciones lineales de la misma; donde S y T están opcionalmente sustituidos en forma independiente en cada caso con un epitope Te hidrato de carbono asociado con cáncer; (b) un lipopéptido unido en forma covalente a (a) de la fórmula: H2N-(aa1)*(aa2)*(aa3)-OH donde aa1 se selecciona en forma independiente en cada caso entre S, T, K, R o C; aa2 se selecciona en forma independiente en cada caso entre S, T, K, R o C; aa3 se selecciona en forma independiente en cada caso entre L o G; * en forma independiente, en cada caso, representa un lípido unido en forma covalente a un residuo de aminoácido; (c) un coadyuvante de fórmula (1), donde al menos uno de R1, R2, R3, R5, R6, y R7 es un grupo fuertemente lipofílico seleccionado entre los restos del grupo de fórmulas (3), donde X, X1, X2, y X3 son en forma independiente -CO- o -CH2-; Z es -NH- u -O; k, m, y r son en forma independiente un entero entre 0 y 30 inclusive; n y q son en forma independiente un entero entre 0 y 6 inclusive; donde Y4 es un espaciador seleccionado entre el grupo que consiste en -O-, -S-, y -NH- donde, al menos uno de Y1R1, Y2R2, Y3R3, Y5R5, Y6R6 e Y7R7 es un equivalente de fosfato monovalente (MPE), donde cada equivalente de fosfato monovalente es, en forma independiente, [a] -R’-C(O)OH donde R’ es un grupo alquilo sustituido o no sustituido de 1 - 4 carbonos, o [b] se selecciona en forma independiente entre el grupo que consiste en -OB(OH)O, -OP(O)(OH)O, -OS(O)(O)(OH)O, y -OP(=O)(OH)-O-P(=O)(OH)O, donde R es hidrógeno, o un grupo alquilo sustituido o no sustituido de 1 - 4 carbonos, y si R es un grupo alquilo sustituido, los sustituyentes son -OH o -NH2, donde R8 se selecciona entre el grupo que consiste en H, OH, OR9, una porción que en combinación con Y8 forma un equivalente de fosfato monovalente como se ha definido, y un resto de fórmula (i) - (viii) del grupo de fórmulas (3) como se ha definido; donde R9 es un grupo alquilo o acilo de entre 1 y 10 carbonos de longitud; y donde la unión glicosídica es a o b; o una sal farmacéuticamente aceptable del mismo; o un coadyuvante de fórmula (2), donde al menos uno de R1, R2, R3, R11, R12 y R13 es un grupo fuertemente lipofílico seleccionado entre el grupo que consiste en los restos de fórmula (i) - (viii) del grupo de fórmulas (3); donde Y4 es un espaciador seleccionado entre el grupo que consiste en -O-, -S-, y -NH- y donde al menos uno de Y1R1, Y2R2, Y3R3, Y11R11, Y12R12 e Y13R13 es en forma independiente un equivalente de fosfato monovalente como se ha definido; donde se aplican las siguientes limitaciones a los compuestos de fórmula (1) y (2): Y1, Y2, Y3, Y5, Y6, Y7, Y11, Y12 e Y13 son espaciadores seleccionados en forma independiente entre el grupo que consiste en -O-, -S-, y -NH-; R1, R2, R3, R5, R6, R7, R11, R12 y R13 son en forma independiente hidrógeno, una porción que, con el grupo comúnmente designado como Y forma un equivalente de fosfato monovalente como se ha definido, o un grupo fuertemente lipofílico seleccionado entre los restos de fórmula (i) - (viii) del grupo de fórmulas (3); los grupos fuertemente lipofílicos de dicho compuesto proveen en conjunto al menos dos cadenas carbonadas principales, y las cadenas carbonadas principales de dichos grupos fuertemente lipofílicos proveen en conjunto al menos 30 átomos de carbono; o una sal farmacéuticamente aceptable del mismo; y (d) uno o más vehículos lípidos. Reivindicación 2: La formulación de vacuna de la reivindicación 1, caracterizada porque el vehículo lípido se selecciona entre dimiristoilfosfatidilglicerol (DMPG), dipalmitoilfosfatidilcolina (DPPC), fosfatidilcolina (PC; lecitina), ácido fosfatídico (PA), fosfatidilglicerol (PG), fosfatidiletanolamina (PE), fosfatidilserina (PS), otros fosfolípidos adecuados además incluyen diestearoilfosfatidilcolina (DSPC), dimiristoilfosfatidilcolina (DMPC), dipalmitoilfosfatidilglicerol (DPPG), diestearoilfosfatidilglicerol (DSPG), ácido dipalmitoilfosfatídico (DPPA); ácido dimiristoilfosfatídico (DMPA), ácido diestearoilfosfatídico (DSPA), dipalmitoilfosfatidilserina (DPPS), dimiristoilfosfatidilserina (DMPS), diestearoilfosfatidilserina (DSPS), dipalmitoilfosfatidiletanolamina (DPPE), dimiristoilfosfatidiletanolamina (DMPE), diestearoilfosfatidiletanolamina (DSPE), o una sal farmacéuticamente aceptable de los mismos, o una combinación de los mismos. Reivindicación 3: La formulación de vacuna de la reivindicación 1, caracterizada porque el lípido unido en forma covalente a un residuo de aminoácido se selecciona en forma independiente en cada caso entre cadenas miristoilo, palmitoilo, laurilo, estearoilo, decanoilo, y octanoilo, o una combinación de las mismas. Reivindicación 4: La formulación de vacuna de la reivindicación 1, caracterizada porque (b) se une al extremo carboxi de (a). Reivindicación 10: La formulación de vacuna de la reivindicación 1, caracterizada porque el coadyuvante tiene una de las estructuras expuestas de fórmula (4) ó (5). Reivindicación 13: Una formulación de vacuna liposomal, caracterizada porque comprende: (a) un glicolipopéptido de estructura: H2N-TSAPDT(Tn)RPAPGS(Tn)T(Tn)APPAHGVTSAPDT(Tn)RPAPGS(Tn)T(Tn)APPAHGVS*S*L-OH SEQ ID Nº 2 donde Tn representa GaINAca1; y * representa, en forma independiente en cada caso, un lípido C14 unido en forma covalente a un residuo serina; (b) un coadyuvante de estructura de fórmula (6), (7), (8) ó (9), o una sal farmacéuticamente aceptable del mismo; y (c) un lípido vehiculo. Reivindicación 16: El coadyuvante de la reivindicación 13, caracterizada porque la sal farmacéuticamente aceptable es una sal de trietilamina. Reivindicación 17: La composición de la reivindicación 13, caracterizada porque el vehículo lípido se selecciona entre DMPG, DPPC o una sal farmacéuticamente aceptable de los mismos, o una combinación de los mismos. Reivindicación 18: La formulación de una cualquiera de la reivindicación 13, caracterizada porque además comprende colesterol. Reivindicación 19: Un método para tratar un individuo que sufre o se sospecha que sufre de un cáncer que expresa un antígeno de MUC1 asociado con tumor, caracterizado comprende administrar al individuo que lo necesite, durante un período de tiempo, una formulación de vacuna liposomal de una cualquiera de la reivindicación 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446332P | 2011-02-24 | 2011-02-24 | |
| US201161470449P | 2011-03-31 | 2011-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085490A1 true AR085490A1 (es) | 2013-10-09 |
Family
ID=46719120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100627 AR085490A1 (es) | 2011-02-24 | 2012-02-24 | Una formulacion de vacuna liposomal |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8889616B2 (es) |
| EP (1) | EP2678005A4 (es) |
| JP (1) | JP2014518841A (es) |
| KR (1) | KR20140023903A (es) |
| CN (2) | CN105193724A (es) |
| AR (1) | AR085490A1 (es) |
| AU (1) | AU2012222188A1 (es) |
| BR (1) | BR112013021779A2 (es) |
| CA (1) | CA2825972A1 (es) |
| MX (1) | MX2013009742A (es) |
| TW (1) | TWI533881B (es) |
| WO (1) | WO2012116225A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104211796A (zh) * | 2013-11-09 | 2014-12-17 | 深圳市康尔诺生物技术有限公司 | 胰腺癌相关肽和热休克蛋白形成的复合物及其应用 |
| WO2015126128A1 (en) * | 2014-02-18 | 2015-08-27 | Kolon Life Science, Inc. | Agent for cancer therapy |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3865139B1 (en) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| AU2016250570B2 (en) | 2015-04-21 | 2021-07-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN106620682A (zh) * | 2017-01-19 | 2017-05-10 | 华中师范大学 | 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法 |
| WO2019035605A2 (ko) * | 2017-08-16 | 2019-02-21 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
| KR102098097B1 (ko) | 2017-08-16 | 2020-05-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
| CN109513002B (zh) * | 2017-09-19 | 2024-02-20 | 台北医学大学 | 缓解发炎的tn疫苗及方法 |
| WO2021110120A1 (zh) * | 2019-12-04 | 2021-06-10 | 华中师范大学 | 一种抗肿瘤疫苗分子及其制备方法和应用 |
| CN111760020B (zh) * | 2020-05-18 | 2023-05-26 | 广州中医药大学(广州中医药研究院) | 一种缀合物及其制备方法和应用 |
| CN111760021B (zh) * | 2020-05-18 | 2023-06-16 | 广州中医药大学(广州中医药研究院) | 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE503349A (es) | 1950-05-31 | |||
| US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5019383A (en) | 1981-01-09 | 1991-05-28 | New York Blood Center, Inc. | Fatty acid carriers for synthetic peptides |
| DE3127503A1 (de) | 1981-07-11 | 1983-02-17 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4464383A (en) | 1981-11-24 | 1984-08-07 | Itaru Yamamoto | Immunomodulator containing trithiazole pentamethine cyanine derivative |
| ZA831547B (en) | 1982-03-15 | 1984-10-31 | New York Blood Center Inc | Fatty acid carriers for synthetic vaccines |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| EP0122151B1 (en) | 1983-04-11 | 1989-02-15 | Meito Sangyo Kabushiki Kaisha | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GR860379B (en) | 1985-02-22 | 1986-06-11 | Akzo Nv | Novel disaccharide and trisaccharide derivatives of the lipid a type |
| WO1986005687A1 (en) | 1985-04-03 | 1986-10-09 | Wisconsin Alumni Research Foundation | Method of preventing diseases caused by gram-negative endotoxin in mammals |
| ATE72123T1 (de) | 1985-04-19 | 1992-02-15 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
| US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
| IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
| JPS63139186A (ja) | 1986-11-29 | 1988-06-10 | Hidetoshi Tsuchida | 三本鎖型リン脂質化合物およびその製造方法 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4868155A (en) | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5041427A (en) | 1989-07-21 | 1991-08-20 | Wisconsin Alumni Research Foundation | Lipid A derivatives |
| JPH0655749B2 (ja) | 1989-09-20 | 1994-07-27 | 日本たばこ産業株式会社 | リピッドａ単糖類縁体 |
| US5871746A (en) | 1990-12-18 | 1999-02-16 | Institut National De La Sainte Et De La Recherche Medicale (Inserm) | Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines |
| US5993823A (en) | 1990-12-18 | 1999-11-30 | Institut Pasteur De Lille | Cytotoxic T lymphocyte-inducing lipopeptides and methods of use |
| FR2670787B1 (fr) | 1990-12-18 | 1995-06-23 | Pasteur Institut | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. |
| ES2044781B1 (es) | 1992-04-14 | 1994-10-01 | Menarini Lab | Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2 |
| WO1993022343A1 (en) | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
| FR2702306B1 (fr) | 1993-03-05 | 1995-04-14 | Alcatel Nv | Procédé d'auto-alignement d'un contact métallique sur un substrat de matériau semi-conducteur. |
| IT1264690B1 (it) | 1993-07-08 | 1996-10-04 | Bracco Spa | Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| DE4408248A1 (de) | 1994-03-11 | 1995-09-14 | Hoechst Ag | Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung |
| WO1995027505A1 (en) | 1994-04-12 | 1995-10-19 | Biomira, Inc. | Cellular immune response-specific antigens and uses therefor |
| CA2189356A1 (en) | 1994-05-02 | 1995-11-09 | Ting Chi Wong | Process for preparation of glycosides of tumor-associated carbohydrate antigens |
| WO1996040236A1 (en) | 1995-06-07 | 1996-12-19 | National Jewish Center For Immunology And Respiratory Medicine | Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof |
| AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| WO1997034921A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Conjugated mucin peptide vaccines |
| AU2284697A (en) | 1996-04-11 | 1997-10-29 | University Of British Columbia, The | Fusogenic liposomes |
| US5910306A (en) | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
| EP0986636B1 (en) | 1997-05-08 | 2008-05-07 | Biomira, Inc. | Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| FR2774687B1 (fr) | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
| AU3596699A (en) * | 1998-02-13 | 1999-08-30 | Gunther Bastert | Specific antibodies against mammary tumor-associated mucin, method for production and use |
| US6043390A (en) | 1998-04-03 | 2000-03-28 | The Regents Of The University Of California | Pentaerythritol lipid derivatives and nucleic-acid complexes |
| FR2776926B1 (fr) | 1998-04-07 | 2003-10-24 | Inst Nat Sante Rech Med | Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination |
| US20020051813A1 (en) | 1999-01-15 | 2002-05-02 | Lawrence Boni | Lipomatrix preparation |
| EP1204423B1 (en) | 1999-08-18 | 2005-03-16 | AltaRex Medical Corp. | Therapeutic antibody against muc-1 antigen and methods for their use |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| DE60030450T2 (de) | 1999-09-08 | 2007-08-30 | Transgene S.A. | Von MUC-1 abgeleitete Peptide |
| WO2001036433A2 (en) | 1999-11-15 | 2001-05-25 | Biomira, Inc. | Synthetic lipid-a analogs and uses thereof |
| US6699846B2 (en) | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
| EP1265632A2 (en) | 2000-03-24 | 2002-12-18 | Biomira, Inc. | Lipopeptide adjuvants |
| ES2164013B1 (es) | 2000-04-14 | 2003-06-16 | Consejo Superior Investigacion | Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales. |
| EP1182210A1 (en) | 2000-08-17 | 2002-02-27 | BASTERT, Gunter, Prof.Dr.med.Dr.h.c. | Epitopes of tumor-associated MUC1 antigen |
| CN1455680A (zh) * | 2000-09-11 | 2003-11-12 | 达纳-法伯癌症协会有限公司 | Muc1胞外域和癌症治疗组合物及方法 |
| WO2002043699A2 (en) | 2000-12-01 | 2002-06-06 | Biomira, Inc. | Preparation of large liposomes by infusion into peg |
| WO2002076485A2 (en) | 2001-03-27 | 2002-10-03 | Biomira, Inc. | Vaccine for modulating between t1 and t2 immune responses |
| JP2005526497A (ja) | 2002-02-04 | 2005-09-08 | ビオミラ，インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
| WO2003089574A2 (en) | 2002-04-15 | 2003-10-30 | Biomira, Inc. | Synthetic glyco-lipo-peptides as vaccines |
| AU2003228966C1 (en) | 2002-05-09 | 2010-05-13 | Oncothyreon Inc. | Lipid A and other carbohydrate ligand analogs |
| GB0212046D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| US20030235610A1 (en) | 2002-06-21 | 2003-12-25 | Piedmont Pharmaceuticals, Llc | Liposomes containing biologically active compounds |
| US9198645B2 (en) | 2003-11-26 | 2015-12-01 | The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology | Controlled vesicle self-assembly in continuous two phase flow microfluidic channels |
| TWI395591B (zh) * | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| PT1896051E (pt) | 2005-06-28 | 2015-01-13 | Oncothyreon Inc | Método de tratamento de pacientes com uma vacina de glicoproteína mucinosa (muc-1) |
| JP5126874B2 (ja) | 2007-05-21 | 2013-01-23 | 国立大学法人神戸大学 | リポソーム製剤の製造方法 |
| MX2011006562A (es) | 2008-12-17 | 2011-09-27 | Oncothyreon Inc | Metodo para elaborar liposomas pequeños. |
-
2012
- 2012-02-23 CN CN201510505238.4A patent/CN105193724A/zh active Pending
- 2012-02-23 AU AU2012222188A patent/AU2012222188A1/en not_active Abandoned
- 2012-02-23 CN CN201280010464.XA patent/CN103781469B/zh not_active Expired - Fee Related
- 2012-02-23 CA CA 2825972 patent/CA2825972A1/en not_active Abandoned
- 2012-02-23 WO PCT/US2012/026385 patent/WO2012116225A2/en active Application Filing
- 2012-02-23 MX MX2013009742A patent/MX2013009742A/es not_active Application Discontinuation
- 2012-02-23 US US13/403,679 patent/US8889616B2/en not_active Expired - Fee Related
- 2012-02-23 KR KR20137024982A patent/KR20140023903A/ko not_active Application Discontinuation
- 2012-02-23 EP EP12749887.1A patent/EP2678005A4/en not_active Withdrawn
- 2012-02-23 BR BR112013021779A patent/BR112013021779A2/pt not_active IP Right Cessation
- 2012-02-23 JP JP2013555576A patent/JP2014518841A/ja active Pending
- 2012-02-24 TW TW101106337A patent/TWI533881B/zh not_active IP Right Cessation
- 2012-02-24 AR ARP120100627 patent/AR085490A1/es unknown
- 2012-07-19 US US13/553,061 patent/US8329639B2/en not_active Expired - Fee Related
-
2014
- 2014-09-17 US US14/488,767 patent/US20150064240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013009742A (es) | 2014-01-31 |
| WO2012116225A3 (en) | 2014-04-24 |
| EP2678005A4 (en) | 2015-06-10 |
| TWI533881B (zh) | 2016-05-21 |
| WO2012116225A9 (en) | 2013-06-27 |
| TW201309326A (zh) | 2013-03-01 |
| US20120219617A1 (en) | 2012-08-30 |
| EP2678005A2 (en) | 2014-01-01 |
| CN103781469B (zh) | 2015-09-16 |
| BR112013021779A2 (pt) | 2017-09-19 |
| CA2825972A1 (en) | 2012-08-30 |
| JP2014518841A (ja) | 2014-08-07 |
| US20120282329A1 (en) | 2012-11-08 |
| KR20140023903A (ko) | 2014-02-27 |
| US8889616B2 (en) | 2014-11-18 |
| US20150064240A1 (en) | 2015-03-05 |
| US8329639B2 (en) | 2012-12-11 |
| AU2012222188A1 (en) | 2013-08-15 |
| CN103781469A (zh) | 2014-05-07 |
| WO2012116225A2 (en) | 2012-08-30 |
| CN105193724A (zh) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085490A1 (es) | Una formulacion de vacuna liposomal | |
| ES2907967T3 (es) | Vesículas extracelulares modificadas y sus usos | |
| Park et al. | Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy | |
| JP6261647B2 (ja) | 新規組成物 | |
| ES2953395T3 (es) | Compuestos para inmunoterapia dirigida | |
| US20220354963A1 (en) | Extracellular vesicle linked to molecules and uses thereof | |
| Henriksen-Lacey et al. | Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen | |
| ES2886999T3 (es) | Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer | |
| Kojima et al. | Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity | |
| JP2016510030A5 (es) | ||
| US9861702B2 (en) | Lipid-conjugated rhamnose for immune system recruitment and oncotherapy | |
| JP2009510133A5 (es) | ||
| JP2022116265A (ja) | 両親媒性化合物、新生抗原及び疎水性担体を含むワクチン組成物、並びにその使用方法 | |
| JP2019196380A (ja) | Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物 | |
| Chakraborty et al. | Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy | |
| EP2792745B1 (en) | Modification of helper t cell-inducing polypeptide | |
| Faham et al. | Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity | |
| WO2022076596A9 (en) | Extracellular vesicle-aso constructs targeting stat6 | |
| KR20180027532A (ko) | 소수성 약물의 효능 개선용 제형 | |
| US20150290306A1 (en) | Compositions and methods for diagnosis and treatment of malignant gliomas | |
| Zheng et al. | Liposome-aided metabolic engineering of tumor surface immunogenicity | |
| WO2021193900A1 (ja) | ポリヌクレオチド－ペプチドコンジュゲートを含む免疫誘導剤およびそれを含む医薬組成物 | |
| WO2024006813A2 (en) | Methods of using extracellular vesicle-aso targeting stat6 | |
| WO2024125676A1 (es) | Variantes sintéticas del gangliósido ngcgm3 y su uso en el tratamiento del cáncer | |
| WO2024118592A2 (en) | Methods of using extracellular vesicle-aso targeting stat6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |